Peptidomimetic compounds and antibody-drug conjugates thereof
US-2016310611-A1 · Oct 27, 2016 · US
Quaternary amine compounds and antibody-drug conjugates thereof
US10556895B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10556895-B2 |
| Application number | US-201715583492-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 1, 2017 |
| Priority date | Dec 3, 2014 |
| Publication date | Feb 11, 2020 |
| Grant date | Feb 11, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to quaternary amine linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A linker-drug intermediate compound selected from: 2. The linker-drug intermediate compound of claim 1 having the structure: 3. The linker-drug intermediate compound of claim 1 having the structure: 4. The linker-drug intermediate compound of claim 1 having the structure: 5. The linker-drug intermediate compound of claim 1 having the structure: 6. The linker-drug intermediate compound of claim 1 having the structure:
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment · CPC title
the antibody targeting a determinant of a tumour cell · CPC title
the drug being a vinca alkaloid · CPC title
not condensed and containing further heterocyclic rings, e.g. timolol · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10556895B2 cover?
- This invention relates to quaternary amine linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
- Who is the assignee on this patent?
- Genentech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D417/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).